Skip to main content

Year: 2020

BI Erhvervsejendomme A/S opdaterer resultatforventningerne for 2020

København Ø, Nov. 11, 2020 (GLOBE NEWSWIRE) —BI Erhvervsejendomme A/S opdaterede den 12. august 2020 sine resultatforventninger for 2020 til et resultat svarende til en egenkapitalforrentning i niveauet 1,4% – 2,4%.Resultatet for 2020 forventes nu at ligge i den øvre ende af dette interval eller lidt over.De opdaterede resultatforventninger for 2020 sker med baggrund i en opjustering af forventningerne til årets driftsafkast af den underliggende ejendomsportefølje i BI Erhvervsejendomme, da det løbende driftsafkast har været mindre påvirket af tab på lejere grundet COVID-19 end tidligere indregnet.Hovedparten af ejendomsporteføljen er udlejet til solide lejere på længere lejekontrakter. Over 75% af den underliggende ejendomsportefølje er kontorejendomme, og den gennemsnitlige lejekontraktlængde i ejendomsporteføljen er ca....

Continue reading

Antiviral Drugs Market Worth USD 44.2 Billion at 3.2% CAGR by 2026; Rising Prevalence of HIV to Fuel Growth: Fortune Business Insights™

Pune, India, Nov. 11, 2020 (GLOBE NEWSWIRE) — The global antiviral drugs market size is set to gain impetus from the improvements in research collaborations of industry giants to develop state-of-the-art therapeutics. Besides, the increasing prevalence of viral diseases would impact the market positively. The study further mentions that the antiviral drugs market size is projected to reach USD 44.2 billion by 2026, thereby exhibiting a CAGR of 3.2% during the forecast period. However, it stood at USD 36.1 billion in 2018. The market is divided into the Middle East and Africa, North America, Europe, Asia Pacific, and Latin America. Out of these, North America held USD 13.9 billion antiviral drugs market revenue in 2018.INDUSTRY DEVELOPMENT:April 2019: Gilead Sciences, one of the major antiviral drugs manufacturers, submitted a supplemental...

Continue reading

Northrop Grumman awards F-35 development contract to Kitron

(2020-11-11) Kitron has been awarded a development contract to update a F-35 test program set (TPS) and provide a repair capability for Kitron and a United States Government (USG) Depot. The contract is for a three-year development program, with a total value of NOK 20 million. The development will be done at Kitron’s facility in Arendal, Norway.The TPS was designed and demonstrated by Kitron under a previous contract. The fully redesigned TPS will enable both Kitron and the USG Depot to detect and isolate faults in the L-Band Pre-Selector (LBPS) Line Replaceable Units (LRUs), which is a module within the F-35 aircraft’s Communication, Navigation and Identification (CNI) avionics suite, developed by Northrop Grumman.“This contract shows that Kitron’s role in the F-35 program extends beyond production to include development projects. It...

Continue reading

Northrop Grumman tildeler Kitron F-35 utviklingskontrakt

(2020-11-11) Kitron er tildelt en utviklingskontrakt for å oppdatere et F-35 testprogramsett (TPS) og tilby reparasjonskapasitet gjennom Kitron og et United States Government (USG) depot. Kontrakten omfatter et treårig utviklingsprogram, med en samlet verdi på 20 millioner kroner. Utviklingen vil bli gjort ved Kitrons anlegg i Arendal.TPS-et ble designet og demonstrert av Kitron i henhold til en tidligere kontrakt. Det fullstendig oppdaterte TPS-et vil sette både Kitron og USG-depotet i stand til  å oppdage og isolere feil i L-Band Pre-Selector (LBPS) Line Replaceable Units (LRU), som er en modul i F-35-flyets kommunikasjons-, navigasjons- og identifikasjonssystem (CNI), utviklet av Northrop Grumman.– Denne kontrakten viser at Kitrons rolle i F-35-programmet ikke bare dekker produksjon, men også inkluderer utviklingsprosjekter. Den peker...

Continue reading

Belships ASA : Tildelt aksjeopsjoner – korrigert

Nedenstående primærinnsidere er tildelt følgende aksjeopsjoner i Belships ASA:Osvald Fossholm: 49.300Etter tildelingen har Fossholm til sammen 100.700 aksjeopsjoner. I tillegg eier han 35.000 aksjer i Belships ASA gjennom sitt selskap Krino Invest AS.Edwin Johansen: 26.900Etter tildelingen har Johansen til sammen 55.050 aksjeopsjoner. I tillegg eier han 8.001 aksjer i Belships ASA.Yngve Aslaksen Gram: 16.200Etter tildelingen har Gram til sammen 16.200 aksjeopsjoner.107.600 aksjeopsjoner er fordelt til øvrige ansatte i Belships ASAInnløsningskurs er satt til NOK 6,20 pr. aksje.Belships har en opsjonsordning for selskapets ansatte og tildelingen er innenfor rammen gitt i fullmakt på generalforsamlingen 14. mai 2020.Oslo, 11. november 2020Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

Continue reading

Injectable Drug Delivery Market to Hit USD 1,251.28 Billion with 12.9% CAGR; Rising Cases of COVID-19 Pandemic to Promote Growth, says Fortune Business Insights™

Pune, Nov. 11, 2020 (GLOBE NEWSWIRE) — The global injectable drug delivery market size is anticipated to rise at a CAGR of 12.9% to reach USD 1,251.28 billion by the end of 2027 owing to the increasing prevalence of various diseases and the need for easy drug delivery to various target sites. Injectable drug delivery helps to provide effective drug delivery experience with speedy delivery. It is also considered as one of the most efficient routes of administration, thus ensuring improved patient experience. As per a report by Fortune Business Insights. The value of this market was USD 483.45 billion in the year 2019 and the forecast period is set between 2020 and 2027. North America accounted for the largest injectable drug delivery market share in 2019 with a revenue of USD 172.67 billion.Major Industry Developments of the Market...

Continue reading

Spirometer Market to Exhibit 4.7% CAGR and Hit USD 716.8 Million by 2027; Owing to Increasing Technological Advancement in Diagnostic Tools Worldwide, states Fortune Business Insights™

Pune, Nov. 11, 2020 (GLOBE NEWSWIRE) — The global spirometer market size is expected to showcase an exponential growth by exhibiting a CAGR of 4.7% between 2020 and 2027. This is attributable to the increasing focus on technological advancement in spirometer owing to the rising prevalence of chronic respiratory diseases globally. The market stood at USD 504.2 million in 2019 and is projected to reach USD 716.8 million by 2027. the market in North America is expected to dominate and hold the largest global spirometry market share in terms of revenue during the forecast period. The North America market was valued at 252.6 million in 2019.Industry Development:July 2020 – Medizintechnik AG announced the launch of a single patient-use, inline filters for its lung function testing devices in response to COVID-19 for safety purpose.March...

Continue reading

Aurora to Report Third Quarter 2020 Financial Results on November 25, 2020

SHENZHEN, China, Nov. 11, 2020 (GLOBE NEWSWIRE) — Aurora Mobile Limited (NASDAQ: JG) (“Aurora Mobile” or the “Company”), a leading mobile developer service provider in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2020 before the open of U.S. markets on Wednesday, November 25, 2020.Aurora’s management will host an earnings conference call on Wednesday, November 25, 2020 at 6:00 a.m. U.S. Eastern Time (7:00 p.m. Hong Kong time on the same day).Due to the outbreak of COVID-19, operator assisted conference calls are not available at the moment. All participants must register in advance to join the conference using the link provided below. Please dial in 15 minutes before the call is scheduled to begin. Conference access information will be provided upon registration.Participant...

Continue reading

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020

Monthly information regarding the total number of voting rights and total number of shares of the Company as of October 31, 2020(Article 223-16 of the General Regulations of the Autorité des Marchés Financiers)Market : NYSE Euronext ParisISIN Code: FR 0010417345* Total net = total number of voting rights attached to shares – shares without voting rightsAttachmentPDF Version

Continue reading

Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social au 31 octobre 2020

Information mensuelle relative au nombre total des droits de voteet d’actions composant le capital social au 31 octobre 2020(Article 223-16 du Règlement Général de l’Autorité des Marchés Financiers)Place de cotation : NYSE Euronext ParisCode ISIN : FR 0010417345*Total net = nombre total de droits de vote attachés au nombre total d’actions – actions privées de droits de votePièce jointeversion PDF

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.